Abstract:Genome‐wide CRISPRCas9 screening identified MDM2 as a potential target for wtT53‐RTK NSCLC cells. MDM2 inhibitor RG7388 selectively kill wtT53‐RTK cells but is less effective against NSCLC cells carrying other genotypes. RG7388 and pemetrexed worked synergistically in blocking proliferation and tumor growth of wtT53‐RTK NSCLC. Background Targeted drugs have greatly improved the therapeutic outcome of non‐small cell lung cancer (NSCLC) patients compared with conventional chemotherapy, whereas about one‐third of patients are so far not suitable for targeted therapy due to lack of known driver oncogenes such as a mutated receptor tyrosine kinase (RTK) genes. In this study, we aimed to identify therapeutic targets for this subgroup of NSCLC patients. Methods We performed genome‐wide CRISPR/Cas9 screens in two NSCLC cell lines carrying wild‐type TP53 and receptor tyrosine kinase (wtTP53‐RTK) genes using a GeCKO v2.0 lentiviral library (containing 123411 sgRNAs and targeting 19050 genes). MAGeCKFlute was used to analyse and identify candidate genes. Genetic perturbation and pharmacological inhibition were used to validate the result in vitro and in vivo. Results The Genome‐wide CRISPR/Cas9 screening identified MDM2 as a potential therapeutic target for wtTP53‐RTK NSCLC. Genetic and pharmacological inhibition of MDM2 reduced cell proliferation and impaired tumour growth in the xenograft model, thus confirming the finding of the CRISPR/Cas9 screening. Moreover, treatment by a selective MDM2 inhibitor RG7388 triggered both cell cycle arrest and apoptosis in several NSCLC cell lines. Additionally, RG7388 and pemetrexed synergistically blocked the cell proliferation and growth of wtTP53‐RTK tumours but had limited effects for other genotypes. Conclusions We identified MDM2 as an essential gene and a potential therapeutic target in wtTP53‐RTK NSCLC via a genome‐wide CRISPR/Cas9 screening. For this subgroup, treatment by RG7388 alone or by its combination with pemetrexed resulted in significant tumour inhibition.

Table S2 from Epigenetic CRISPR Screens Identify Npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Table S1 from Epigenetic CRISPR Screens Identify <i>npm1</i> As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Genome-wide CRISPR Screens Reveal a Wnt–FZD5 Signaling Circuit As a Druggable Vulnerability of RNF43-mutant Pancreatic Tumors

Figure S10 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Figure S15 from in Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Figure S5 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Figure S6 from in Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

Figure S16 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions

CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells

In Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma